Lung cancer is a malignant tumor characterized by uncontrolled cell division. Symptoms include coughing, weight loss and shortness of breath. “Guardant 360” is a non-invasive liquid biopsy. It is a blood test that helps in the detection of DNA segments in blood. A well-known hospital called as Soroka Hospital that is located in Southern Israel has given out an outstanding approach that could help a lot to test the specific type of lung cancer.
Hebrew language website “Ynet” reported on Monday that Guardant 360 biopsy can help to match the accurate treatment for lung cancer patients. In the case of cancer, this test helps to identify the DNA segments that are causing the production of cancerous tumors.
The US Food and Drug Administration has approved some drugs that could be used to treat the patients with lung cancer who had genetic modifications in their cells. In the research, scientists examined 116 patients with advanced stage non-small-cell lung carcinoma. All of them could be treated by approved drugs.
This is a precise treatment that can be very useful in identifying the correct treatments for cancer patients. A simple blood test is a solution which identified the DNA segments produced by cancerous cells. Those marked segments tell the type of drugs suitable for the disease. This is a great achievement that is the fruit for the hardworking scientists at the Soroka University of Israel.
The progress wasn’t only confined to the specific state but benefits the world all over.